Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Medical guidelines already recognize that Asian Americans develop diabetes and obesity-related disease at lower BMIs — but insurance coverage for GLP-1 medications hasn't caught up. A South Asian physician highlights the contradiction: screened for diabetes at BMI 23, yet denied treatment until BMI 30. The clinical science supports lower thresholds, and the fix requires no new laws — just payers applying their own guidelines consistently.
Medical guidelines already acknowledge that Asian Americans develop diabetes and cardiovascular disease at lower body weights than white adults — the ADA recommends diabetes screening starting at a BMI of 23 for Asian patients. But when it comes to GLP-1 receptor agonists like semaglutide (Wegovy) or tirzepatide (Zepbound), FDA eligibility thresholds remain anchored at BMI 30 (or 27 with a comorbidity) — thresholds built from clinical trials designed around Western body compositions.
A South Asian internal medicine physician and former Joslin Diabetes Center fellow lays out the contradiction: the same BMI of 26.5 that triggers annual diabetes screening is simultaneously used to deny GLP-1 coverage. Research supports this concern — a 2025 trial (STEP 11) showed semaglutide produced 17.6% weight loss in participants below BMI 30 in South Korea and Thailand, and GLP-1s prevented major cardiac events in nearly twice as many Asian patients as white patients across eight cardiovascular outcome trials.
By the Numbers
Why it matters: As GLP-1 coverage contracts — Medi-Cal and MassHealth have already dropped weight-loss coverage — patients with always-marginal eligibility lose access first. Payers already cite ADA and AHA guidelines when it suits them; adopting ethnicity-adjusted BMI thresholds for treatment access requires no new legislation, just consistency.
